Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 20, 2024 | June 24, 2024 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Prime Medicine, Inc.PRME · Entity 5281 | Director | June 05, 2026 | June 08, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | June 18, 2020 | June 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,120 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 2,120 · Balance 2,120 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.45 · Expires 2034-06-20 | Direct | 11,774 |
Reported balance
After 2024-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-20 · Grant · Acquired 11,774 · Balance 11,774 F3: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,665 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 21,665 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F5: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 26,232 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 26,232 F3: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,232 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 31,232 F4: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
F4: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
F5: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Prime Medicine, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2036-06-05 | Direct | 75,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 603 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 603 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
bluebird bio, Inc.
Report date June 18, 2020 · Filed June 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,832 |
Last balance in matching sequence
After 2020-06-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-18 · Grant · Acquired 156 · Balance 5,332 F1: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. Row 2 · 2020-06-18 · Grant · Acquired 1,500 · Balance 6,832 F1: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.09 · Expires 2030-06-18 | Direct | 3,000 |
Reported balance
After 2020-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-18 · Grant · Acquired 3,000 · Balance 3,000 F2: This option vests 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders.
F2: This option vests 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2018 Filed May 29, 2018 10:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 39,774 | $90.11 | $3,584,035.14 |
DisclosureSEC source: 0001209191-18-033652 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $90.00 to $90.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 49,374 | $0.30 | $14,935.64 |
DisclosureSEC source: 0001209191-18-033652 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 100 | $84.35 | $8,435.00 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,814 | $83.56 | $235,137.84 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $83.29 to $84.20. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 10,086 | $82.88 | $835,927.68 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,914 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.29 to $83.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · derivative · entry 9 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,113 | $79.49 | $167,962.37 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 6 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.16 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,390 | $78.59 | $266,420.10 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 5 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,113 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.11 to $79.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,340 | $77.76 | $259,718.40 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,503 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $77.10 to $78.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,600 | $76.40 | $198,640.00 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,843 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.02 to $77.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,557 | $75.54 | $117,615.78 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,443 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.00 to $75.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 10,085 | $81.30 | $819,910.50 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.80 to $81.77. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,915 | $80.38 | $234,307.70 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,085 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.80 to $80.79. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 24,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011239 · doc4.xml · derivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 Underlying: Common stock · 24,375 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 97,500 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011239 · doc4.xml · derivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common stock · 97,500 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 4,460 | $79.23 | $353,365.80 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.03 to $79.72. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 8,540 | $78.50 | $670,390.00 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,460 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.01 to $79.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:40 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-007529 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 23,572 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,567 Underlying: Common stock · 23,572 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,966 | $82.22 | $243,864.52 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.00 to $82.62. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 11,369 | $81.40 | $925,436.60 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.00 to $81.95. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 9,237 | $80.35 | $742,192.95 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,335 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.96. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 23,572 | $0.30 | $7,130.53 |
DisclosureSEC source: 0001209191-18-006004 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 13,533 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · derivative · entry 8 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,159 Underlying: Common stock · 13,533 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 13,533 | $80.01 | $1,082,775.33 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 13,533 | $0.30 | $4,093.73 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 20 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-005584 · doc4.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,139 Underlying: Common stock · 20 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 20 | $80.01 | $1,600.20 |
DisclosureSEC source: 0001209191-18-005584 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 20 | $0.30 | $6.05 |
DisclosureSEC source: 0001209191-18-005584 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 32,875 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,962 Underlying: Common stock · 32,875 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 32,875 | $80.01 | $2,630,328.75 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 32,875 | $0.30 | $9,944.69 |
DisclosureSEC source: 0001209191-18-005357 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 53,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · derivative · entry 8 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,692 Underlying: Common stock · 53,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 6,597 | $74.80 | $493,455.60 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 5 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $74.56 to $75.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 10,914 | $74.11 | $808,836.54 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,597 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $73.56 to $74.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 22,304 | $73.02 | $1,628,638.08 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,511 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $72.56 to $73.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 13,185 | $71.77 | $946,287.45 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,815 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $71.50 to $72.42. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 53,000 | $0.30 | $16,032.50 |
DisclosureSEC source: 0001209191-18-003637 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 19,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065249 · doc4.xml · derivative · entry 9 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 19,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · ownership.nature: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 105,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065249 · doc4.xml · derivative · entry 8 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 105,225 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · ownership.nature: The shares are held of record by the Amy P. Schenkein 2015 Denali Qualified Annuity Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 19,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065249 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 19,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · ownership.nature: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 105,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065249 · doc4.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 105,225 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by the David P. Schenkein 2015 Denali Qualified Annuity Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 19,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-065249 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · ownership.nature: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 105,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-065249 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 105,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · ownership.nature: The shares are held of record by the Amy P. Schenkein 2015 Denali Qualified Annuity Trust, for which the Reporting Person serves as a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.